Takeda Pharmaceutical Aktie
| 24,92EUR | -0,26EUR | -1,03% |
WKN: 853849 / ISIN: JP3463000004
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 97,19 |
| BlackRock Fund Advisors | 3,48 |
| Nomura Asset NEXT FUNDS TOPIX ETF (1306) | 3,28 |
| Sumitomo Mitsui Trust Asset Management Co., Ltd. | 3,20 |
| BlackRock Japan Co. Ltd. | 2,26 |
| Nikko Asset Management Co., Ltd. | 2,18 |
| Government Pension Fund - Global (The) | 1,64 |
| Nikko Asset Listed Index TOPIX ETF (1308) | 1,58 |
| Nippon Life Insurance Co. | 1,56 |
| Daiwa Asset iFreeETF TOPIX (Yearly Dividend Type) (1305) | 1,49 |
| Vanguard Total International Stock Index Fund | 1,36 |
| Takeda Science Foundation | 1,13 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 47 495 | 47 099 | 47 347 | 49 095 | 49 281 |
| Umsatz pro Mitarbeiter in Mio. EUR | 69,30 | 67,90 | 75,38 | 82,03 | 86,52 |
Bilanz (in Mio. JPY) - Aktiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 2 469 432 | 2 712 893 | 2 593 642 | 2 397 956 | 2 558 580 |
| Summe Anlagevermögen | 10 351 662 | 10 199 400 | 10 584 376 | 11 559 794 | 12 550 212 |
| Summe Aktiva | 12 821 094 | 12 912 293 | 13 178 018 | 13 957 750 | 15 108 792 |
Bilanz (in Mio. JPY) - Passiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Gesamtverschuldung/ -verbindlichkeiten | 5 462 763 | 5 071 783 | 4 810 649 | 4 861 692 | 5 463 391 |
| Summe Fremdkapital | 8 093 608 | 7 735 116 | 7 494 496 | 7 603 080 | 7 834 788 |
| Summe Eigenkapital | 4 727 486 | 5 177 177 | 5 683 523 | 6 354 671 | 7 274 005 |
| Summe Passiva | 12 821 094 | 12 912 293 | 13 178 019 | 13 957 751 | 15 108 793 |
Adresse
| 4-1-1 Dosho-machi, 540-8645 Osaka | |
| Telefon | +81 (6) 6204-2111 |
| Fax | +81 (6) 6204-2880 |
| Internet | http://www.takeda.com |
Management
|
Andrew S. Plump
Director, President-Research & Development |
|
Chris Slavinsky
VP-External Innovation & Head-Gastroenterology |
|
Christophe Weber
President, CEO & Representative Director |
|
Christopher David O'Reilly
Global Head-Investor Relations |
|
Emiko Higashi
Independent Outside Director |
|
Gabriele Ricci
Chief Data & Technology Officer |
|
Giles Platford
President-Europe & Canada |
|
Haruhiko Hirate
Corporate Communications & Public Affairs Officer |
|
Ian T. Clark
Independent Director |
|
Jean-Luc Butel
Independent Outside Director |
|
John M. Maraganore
Independent Outside Director |
|
Julie So-Young Kim
President-Plasma-Derived Therapies |
|
Kimberly A. Reed
Independent Outside Director |
|
Koji Hatsukawa
Independent Outside Director |
|
Lauren Duprey
Chief Human Resources Officer |
|
Marcello Agosti
Global Business Development Officer |
|
Mark Etherton
Medical Director |
|
Masami Iijima
Chairman |
|
Michael E. Mendelsohn
Chief Medical & Scientific Officer |
|
Michel Orsinger
Independent Outside Director |
|
Miki Tsusaka
Independent Outside Director |
|
Milano Furuta
Chief Financial Officer & Director |
|
Mwana Lugogo
Chief Ethics & Compliance Officer |
|
Norimasa Takeda
Chief Accounting Officer & Corporate Controller |
|
Ramy Riad
CFO-Global Plasma Derived Therapies |
|
Ricardo Marek
President-Growth & Emerging Markets Business Unit |
|
Rupa Cornell
Vice President-Legal |
|
Salvatore Alesci
Head-R & D Global Science & Biomedical Policy |
|
Satoru Takemoto
General Manager-Sales |
|
Steven H. Gillis
Independent Outside Director |
|
Takashi Okubo
Global Head-Investor Relations & Global Finance |
|
Teresa Bitetti
President-Global Oncology Business Unit |
|
Yoshiaki Fujimori
Independent Outside Director |
|
Yoshihiro Nakagawa
Executive Officer & Global General Counsel |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
